Captor Therapeutics®

Inspired by nature, we are reprogramming protein fate to treat the untreatable...

Factsheet FY 2022

Captor Therapeutics S.A
ul. Duńska 11
54-427 Wrocław, Poland

Captor Therapeutics GmbH
Hegenheimermattweg 167A
4123 Allschwil, Switzerland
Contact: t.shepherd@captortherapeutics.com

Captor Therapeutics is a biopharmaceutical Company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Captor Therapeutics is a Polish-Swiss Company.

Our competitive advantages

- New partnership with global pharmaceutical company **Ono Pharmaceutical Co. Ltd** (up to EUR 197 M in up-front & success-based milestone payments, plus royalties on global sales).
- Differentiated fully owned pipeline in oncology and inflammation
- World leading E3 ligase discovery unit
- TPD platform comprising molecular glues, bifunctional degraders and E3 ligases

Targeted Protein Degradation (TPD) offers advantages over classical small molecules by: 1. removing all pathological functions; 2. potentially overcoming cancer resistance; 3. prolonged efficacy due to uncoupling pharmacokinetics from pharmacodynamics.

Updated Three-Year Strategic Objectives

- Initiate Captor's clinical development of its leading projects CT-01 (Hepatocellular carcinoma) and CT-03 (hematological malignancies) in 2023 and 2024 respectively, with clinical data readouts in 2024 and 2025.
- Advance Captor's early pipeline assets in inflammation (CT-02, CT-05) to *in-vivo* proof of efficacy in 2023.
- Deepen and expand the Optigrade™ platform through degrading targets with high clinical potential using Captor's novel E3 ligase ligands and expanding the use of high potency degraders into the antibody drug conjugate space. Exploiting partnering opportunities in these new areas.
- Build on Captor's solid European listing and investor base to attract US investors, potentially culminating in the future in a US NASDAQ presence (through an ADR or direct listing), subject to favorable capital market conditions.

Fully owned pipeline

#	Indications	Modality	Discovery	Preclinical*	IND Filing	Phase IA/IB	Phase II	Next milesotne
CT-01	Hepatocellular carcinoma, lung cancer, NET tumors **GSPT1, NEK74, SALL4**	MG						✓ IND/CTA – 2023 ✓ Entering phase I clinical in 2023
CT-02	Autoimmunity, CNS, metabolism, oncology **NEK7**	MG						
CT-03	Liquid & solid tumours **MCL-1**	BID						✓ IND/CTA – 2024 ✓ Entering phase I clinical in 2024
CT-05	Autoimmunity, oncology, transplantation,metabolism **PKC_θ**	BID						
New target projects	Autoimmunity, Cancer	MG BID						
New E3 ligase degraders	Autoimmunity, Cancer	MG BID						

Preclinical stage include IND-enabling studies, **BID - Bi-functional Degrader; **MG** - Molecular Glue*

Assumed stage at the end of 2025

Key R&D Announcements

CT-01 targeting GSPT1, SALL4 and (new disclosure) NEK7

- CT-01 / CPT-6281 is currently undergoing IND/CTA-enabling studies with the first clinical trial expected to start at the end of 2023. The first indication is Hepatocellular Carcinoma (HCC).
- CPT-6281 is a first-in-class degrader of three targets: GSPT1, SALL4, and NEK7. GSPT1 is a protein involved in the termination of translation, SALL4 is a transcription factor often over-expressed in HCC patients and correlating with poor prognosis, and NEK7 is a protein in which degradation leads to a reduction in IL-1b production, a well-known pro-carcinogenic factor.
- Moreover, CPT-6281 is particularly well suited for liver, lung, and neuroendocrine tumors since it is a prodrug that is activated by an enzyme present in high concentration in these tissues.

CT-02 targeting (new disclosure) NEK7

- The selective degradation of NEK7 alone has many potential benefits as a treatment of several autoimmune diseases. Such NEK7 degradation allows the modulation of the inflammasome, a complex that plays a critical role in the regulation of the inflammatory response.
- Captor believes that selective NEK7 degraders have the potential to overcome the limitations of previous NLRP3 inhibitor drugs related to increased susceptibility to infection. Importantly, it is established that NEK7 pro-inflammatory activity is largely driven by its scaffolding function which is not affected by inhibitors, therefore classical inhibition of NEK7's kinase function doesn't provide therapeutic benefit. It is expected that selective degradation of NEK7 removes the NEK7 scaffolding function leading to potent inflammatory inhibition.

Pre-clinical studies have revealed the following benefits of CT-02:

- Effective NEK7 degradation at low concentrations *in vitro*, *ex vivo* and *in vivo*
- Degradation of NEK7 is correlated with the desired biological effects on the inflammatory response
- Optimised compounds with good pharmacokinetics in animals have been developed
- Compounds with the ability to cross the blood-brain-barrier have been identified and provide opportunity for further development in the area of neurodegeneration

CT-05 targeting (new disclosure) PKC_θ (PKC theta)

- PKC_θ plays an important role in the modulation of T cells by limiting the suppressive function of T cells. It is therefore expected that degrading the PKC_θ protein would lead to an increased T cell suppressive function. PKC_θ is a high-value target with opportunities in certain autoimmune diseases, such as allergy, psoriasis, and inflammatory bowel disease, as well as certain malignancies, such as breast and gastrointestinal cancer.
- Importantly, the approach behind CT-05 is partially de-risked thanks to:
  - the PKC_θ protein acts via the CD3/CD28 – IL-2/IL-17 pathway. The IL-17 pathway is a clinically validated pathway in autoimmune diseases such as psoriasis with established modulators,
  - the potential of the PKC_θ protein pathway is underpinned by BMS's latest in-licensing of Exscientia's PKC_θ inhibitor EXS 4318.

In preclinical studies, CT-05 has demonstrated attractive features that differentiate CT-05 from inhibitors that failed in clinical trials due to side effects:

- Potent degradation and first-in-class selectivity profile of the molecular target PKC_θ in immune cells *in vitro*
- Desired effect on *ex vivo* immune cells
- No effect on non-immune cells

Investor Factsheet FY 2022

Inspired by nature, we are reprogramming protein fate to treat the untreatable...

Employees (data as of 31.12.2022)

Number of employees	111
Number of research staff	98

50%

Research staff with PhD

Consolidated statement of financial assets position (PLN, m)



Available funding secured

(PLN, M, as of 31.12.2022)



PLN 91 M
Cash, short-term bonds

PLN 69 M
Agreements with NCBR

Total PLN 160 M

Shareholding Structure – 31.12.2022



Share capital	*Shareholder*
22,92%	Michał Walczak
14.23%	Paweł Holstinghausen Holsten
8.18%	Sylvain Cottens
7.27%	Funds Managed by Nationale-Nederlanden - Powszechne Towarzystwo Emerytalne S.A.
47,41%	Others

Stock exchange info

Company listed on Warsaw Stock Exchange (GPW): CAPTORTX

Market capitalization (max. March 2023): PLN 719 M

IPO value: ~ PLN 150 M

IPO date: 19 Apr 2021

Captor Therapeutics®

www.captortherapeutics.com

investors.relations@captortherapeutics.com